Evidence map›Paper›PMID 41820978›Full record

ArticleAIDS research and therapy2026

Rapid identification of antigen-specific monoclonal antibodies from HIV-1 elite controllers using the Beacon platform.

Xiangyu Zhang, Xinyuan Zheng, Rishen Liang, Lina Huang, Yu Shi, Zhi Zhang, Chengrui Yin, Chengchao Ding, Jiabing Wu, Jianjun Wu and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in AIDS research and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xiangyu ZhangDepartment of Infectious Diseases, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
Xinyuan ZhengDepartment of Infectious Diseases, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
Rishen LiangDepartment of Infectious Diseases, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
Lina HuangDepartment of Infectious Diseases, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
Yu ShiSchool of Public Health, Anhui Medical University, Hefei, Anhui, China.
Zhi ZhangSchool of Public Health, Anhui Medical University, Hefei, Anhui, China.
Chengrui YinDepartment of Infectious Diseases, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
Chengchao DingDepartment of Infectious Diseases, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
Jiabing WuDepartment of HIV and AIDS Control and Prevention, Anhui Provincial Center for Disease Control and Prevention, Hefei, Anhui, China.
Jianjun WuSchool of Public Health, Anhui Medical University, Hefei, Anhui, China. wujianjun823@126.com.
Yong GaoDepartment of Infectious Diseases, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China. ygao387@ustc.edu.cn.

Funding

Anhui Provincial Natural Science Foundation No. 2208085MH26
6 · The paper itself

Abstract

Elite controllers (ECs) are rare human immunodeficiency virus (HIV)-infected individuals who manage viral replication without antiretroviral therapy. While their cellular immunity is well characterized, humoral responses remain limited, which provides an uncommon window into antibody responses to HIV-1. Using single-cell functional screening, this study aimed to isolate and characterize HIV-1 envelope (Env)-specific monoclonal antibodies (mAbs) from ECs. The Beacon platform was used for enrichment, activation, and screening of cluster of differentiation 27

Indexed as

Antibodies, MonoclonalHIV-1HIV AntibodiesHIV InfectionsHIV Long-Term SurvivorsAntibodies, NeutralizingB-Lymphocytesenv Gene Products, Human Immunodeficiency VirusHumansImmunoglobulin GMemory B CellsSingle-Cell AnalysisAntibodies, MonoclonalAntibodies, Neutralizingenv Gene Products, Human Immunodeficiency VirusHIV AntibodiesImmunoglobulin GAntigen-specific B cellsBeacon platformElite controllerHIV-1Monoclonal antibody

Identifiers

PMID41820978
PMCPMC13097949

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.